[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605663":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":58,"collaborators":25,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":25,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":25,"enrollmentInfo":70,"targetDuration":25,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":25,"overallStatus":37,"whyStopped":25,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"B-CAP group","EXPERIMENTAL","Patients will a 10-day course of bismuth, metronidazole, tetracycline four times daily, and vonoprazan 20 mg twice daily.",[13],"Drug: Potassium-Competitive Acid Blocker",{"label":15,"type":16,"description":17,"interventionNames":18},"PPI group","ACTIVE_COMPARATOR","Patients will receive a 10-day course of bismuth, metronidazole, tetracycline four times daily, and rabeprazole 20 mg twice daily.",[19],"Drug: Proton Pump Inhibitor",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","Potassium-Competitive Acid Blocker",[9],null,{"type":22,"name":27,"description":17,"armGroupLabels":28,"otherNames":25},"Proton Pump Inhibitor",[15],[30],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},"Mohamed G Flefel, MD","CONTACT","00201009156988","mohamed.galal@med.tanta.edu.eg",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Tanta","El-Gharbia","31527","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.00192,30.78847,{"lat":47,"lon":46},[50,51,54,56],{"name":31,"role":32,"phone":33,"phoneExt":25,"email":34},{"name":52,"role":53,"phone":25,"phoneExt":25,"email":25},"Nashwa S Abdeen, MD","PRINCIPAL_INVESTIGATOR",{"name":55,"role":53,"phone":25,"phoneExt":25,"email":25},"Ashraf A Aboismail, MD",{"name":57,"role":53,"phone":25,"phoneExt":25,"email":25},"Ahmed F Selim, MD",{"type":53,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Mohamed Galal Flefel","Lecturer of Internal Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt.","100605663","potassium-competitive-acid-blocker-versus-proton-pump-inhibitor-as-a-part-of-bismuth-based-quadruple-therapy-for-treatment-of-helicobacter-pylori-infection-100605663",false,"NCT07165444","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection","Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged ≥18 years.\n* Both sexes.\n* Confirmed Helicobacter pylori infection by stool antigen (3rd-gen ELISA) or urea breath test (UBT).\n* No prior eradication therapy.\n\nExclusion Criteria:\n\n* Prior Helicobacter pylori treatment.\n* Use of antibiotics, proton pump inhibitor, or bismuth in the prior 4 weeks.\n* Gastric surgery history.\n* Major organ failure.\n* Pregnancy or lactation.\n* Known allergy to study drugs.","ALL","18 Years",{"count":71,"type":72},320,"ESTIMATED","INTERVENTIONAL",[75],"NA","This study aims to compare the eradication rate, safety, and patient adherence between potassium-competitive acid blockers (P-CABs) and proton pump inhibitor-based bismuth quadruple therapy in patients with Helicobacter pylori infection.",[23,27,78,79,80],"Bismuth Based Quadruple Therapy","Treatment","Helicobacter Pylori Infection","2025-09-11",{"date":83,"type":84},"2025-09-12","ACTUAL",{"date":81,"type":84},{"date":87,"type":72},"2026-02-01",{"name":5,"class":6},1]